Analysts Set $26.67 Target Price for Synthorx Inc (NASDAQ:THOR)

Share on StockTwits

Synthorx Inc (NASDAQ:THOR) has received an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus target price of $26.67 for the company and are predicting that the company will post ($0.38) EPS for the current quarter, according to Zacks. Zacks has also assigned Synthorx an industry rank of 74 out of 256 based on the ratings given to its competitors.

A number of research analysts have commented on THOR shares. Zacks Investment Research raised shares of Synthorx from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Saturday, March 16th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Synthorx in a research report on Wednesday, May 1st. Svb Leerink reissued an “outperform” rating on shares of Synthorx in a research report on Monday, March 18th. Finally, Leerink Swann started coverage on shares of Synthorx in a research report on Friday, March 15th. They set an “outperform” rating on the stock.

Several institutional investors have recently modified their holdings of the company. Strs Ohio purchased a new position in shares of Synthorx in the 1st quarter worth approximately $38,000. Matisse Capital grew its position in shares of Synthorx by 16.9% in the 1st quarter. Matisse Capital now owns 64,333 shares of the medical instruments supplier’s stock worth $1,310,000 after buying an additional 9,300 shares during the last quarter. Monashee Investment Management LLC purchased a new position in shares of Synthorx in the 4th quarter worth approximately $435,000. Dean Capital Investments Management LLC purchased a new position in shares of Synthorx in the 4th quarter worth approximately $827,000. Finally, Emory University purchased a new position in shares of Synthorx in the 1st quarter worth approximately $2,439,000. 66.08% of the stock is currently owned by hedge funds and other institutional investors.

THOR traded up $0.37 during trading on Tuesday, hitting $12.59. 1,387 shares of the company traded hands, compared to its average volume of 85,795. The company has a market cap of $392.75 million and a P/E ratio of -1.92. The stock has a 50-day moving average price of $14.56. Synthorx has a 1 year low of $11.00 and a 1 year high of $23.53.

Synthorx (NASDAQ:THOR) last released its quarterly earnings data on Tuesday, April 30th. The medical instruments supplier reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.03). On average, sell-side analysts anticipate that Synthorx will post -1.65 EPS for the current year.

About Synthorx

Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Further Reading: Golden Cross

Get a free copy of the Zacks research report on Synthorx (THOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.